Noviral comments on Spanish COVID-19 antibody study – ”Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study”

As one of the leading test suppliers Noviral keeps close track of the development in regard to the ongoing COVID-19 pandemic. Noviral now comments on the world’s largest study on the presence of IgG-antibodies in a population. The Spanish study has been published in the medical journal The Lancet.

“Noviral regards the ongoing research efforts in the wake of the COVID-19 pandemic of highest importance to be able to open up the society safely and securely. Noviral has since the start through donating point-of-care tests contributed to research and national studies. Recently Spanish scientists published the largest study in the world on trying to map the spread of COVID-19. The rapid antibody point-of-care test Noviral provides plays a key role in that study.

The study was carried out by the Carlos III Institute for Health and Spain’s National Statistics Institute, and thanks to that official backing, researchers were able to obtain samples from more than 36,000 randomly selected households across the country. A total of 61,075 people agreed to participate in the study, which was carried out between April 27 and May 11. Participants answered a questionnaire on coronavirus symptoms, were given a point-of-care finger prick test and had the option to donate blood for further laboratory testing which 51,958 of the people in the study did. In order to check for antibodies the scientists used two different antibody tests to identify IgG-antibodies against two different structures of protein in the SARS-COV-2 virus; Novirals point-of-care test targeting the S-protein and Abbots Architect lab test targeting the N-protein.

Noviral welcomes the preferred method of using two separate tests to identify different types of IgG-antibodies in order to estimate the presence of antibodies in the population. The Noviral point-of-case test showed positive in 1,7% of the cases where Abbott showed a negative test result (relative specificity 98,3%) and negative in 20,4% of the cases Abbott deemed positive (relative sensitivity 79,6%). The two tests identify different IgG-antibodies attached to different proteins which makes it difficult to put too much emphasis in comparing specificity and sensitivity between the two. The working theory is that antibodies to S-protein, the one Novirals point-of-care test detects, develops in a later stage compared to the antibodies developed to the N-protein that the Abbott test identifies. This would serve as an adequate explanation to why the two tests estimated a somewhat different level of antibodies among those who reported themselves to have had a positive PCR-test.

One of the most practical conclusions from the study survey is that the Noviral point-of-care test yielded comparable epidemiological information while having a greater uptake, lower cost, and easier implementation in comparison to other types of tests. A high-performance point-of-care test such as the ones provided by Noviral could according to the scientists be a suitable option for large seroepidemiological studies and additionally, as the two tests addressed different viral proteins, they might be providing complementary information. This type of seroepidemiological studies could prove the best way to map the spread of COVID-19, especially since a vast amount of people infected showed no symptoms.

Noviral will, on a national and international level, keep monitoring the development on all crucial levels and Noviral encourage scientists and authorities to maintain a continuous dialogue in order to clarify differences in the types of tests available and also in order to develop a joint strategy as to when and where the different types of tests should and could be utilized. This would provide an increased possibility to maintain a scientifically, socio-economic and population safe test strategy.”


”Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study”

  • A total of 61 075 Spaniards is included in the study.
  • The majority turned out negative and did not have antibodies.
  • Based on the study the scientist recommends to keep following the preventive measures recommended by authorities.
  • Test method: Noviral point-of-care test (to SARS-CoV-2 S-protein) and Abbot lab test (to SARS-CoV-2 N-protein).
  • Comparison and result between the different test methods varies due to the different measured values.


Antibody test Serological test, antibody test, shows if you have had COVID-19 and developed antibodies and hence in total or partly would be immune to COVID-18.

PCR PCR-tests is used to detect an ongoing or recent COVID-19-infection.

PoC Point-of-care tests also known as rapid tests.

Lab tests Tests analyzed in a laboratory.

Specificity (also called the true negative rate) measures the proportion of actual negatives that are correctly identified as such (e.g., the percentage of healthy people who are correctly identified as not having the condition).

Sensitivity (also called the true positive rate, the epidemiological/clinical sensitivity, the recall, or probability of detection[1] in some fields) measures the proportion of actual positives that are correctly identified as such (e.g., the percentage of sick people who are correctly identified as having the condition).

IgG Detectable 1-6 weeks after an infection has passed. These antibodies indicate that you may have had COVID-19 in the recent past and have developed antibodies that may protect you from future infection. It is unknown at this point how much protection antibodies might provide against reinfection, but the theory is the immunity would last at least 1-3 months.

IgM IgM is usually the first antibody produced by the immune system when a virus attacks and can be detected 1-6 weeks after an infection has passed. There is no known knowledge as to how long the remain or what IgM means regarding immunity.

SARS-CoV-2 COVID-19 is caused by the virus SARS-CoV-2.

For more information:

Anders Åker, CCO Noviral
046-703 648 422,

About Noviral
Noviral is a company founded following the Covid-19-pandemic with the vision to help employers and organizations to return their employees efficiently and safely to the workplace. Noviral offers high quality Covid-19-tests, planning and execution of testing, experts and advise along with digital solutions to track and follow symptoms and the spread of infection on a large scale in a long term. The overall concept from Noviral provides support and structure needed by companies to be able to proceed towards a normal every day. Noviral also supports research and authorities by sharing collected data. The company is founded by entrepreneurs and investors within medicine, technique, and logistics and since the beginning Noviral has had a medical advisory board providing advice and expertise within medicine, research, and immunology.